drugset / Trial / NCT05236036
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Phase 1
Active not recruiting
60 enrolled
Northwestern University
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma. Mycophenolate mofetil is an immunosuppressant drug that is typically used to prevent organ rejection in transplant recipients. However, mycophenolate mofetil may also help chemotherapy with temozolomide work better by making tumor cells more sensitive to the drug. The purpose of this trial is to determine if mycophenolate mofetil combined with temozolomide can stop glioblastoma.
Timeline
- Start
- 2022-08-08
- Primary completion
- 2026-01-12
- Completion
- 2029-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | — | Oral |
| Background | Temozolomide | Small molecule | — | Oral |